ArTS Archivio della ricerca di Trieste

GENERALI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.800
EU - Europa 12.719
AS - Asia 10.846
SA - Sud America 1.464
AF - Africa 307
OC - Oceania 41
Continente sconosciuto - Info sul continente non disponibili 7
Totale 49.184
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.469
PL - Polonia 4.924
SG - Singapore 3.864
CN - Cina 2.283
IT - Italia 2.164
HK - Hong Kong 1.323
SE - Svezia 1.154
BR - Brasile 1.142
VN - Vietnam 1.069
DE - Germania 728
FR - Francia 523
KR - Corea 499
RU - Federazione Russa 476
NL - Olanda 475
UA - Ucraina 473
FI - Finlandia 447
BD - Bangladesh 405
TR - Turchia 371
GB - Regno Unito 327
IN - India 277
IE - Irlanda 273
BG - Bulgaria 266
CA - Canada 140
AR - Argentina 125
ES - Italia 114
MX - Messico 110
JP - Giappone 88
MA - Marocco 81
IQ - Iraq 80
AT - Austria 75
ZA - Sudafrica 68
SA - Arabia Saudita 61
BE - Belgio 55
PK - Pakistan 53
ID - Indonesia 52
MY - Malesia 52
EC - Ecuador 45
IL - Israele 40
RO - Romania 40
AU - Australia 36
CO - Colombia 34
PH - Filippine 34
TH - Thailandia 34
CL - Cile 33
VE - Venezuela 32
CH - Svizzera 29
EG - Egitto 27
JO - Giordania 27
KE - Kenya 25
TN - Tunisia 25
IR - Iran 24
AZ - Azerbaigian 21
DZ - Algeria 21
TW - Taiwan 21
AE - Emirati Arabi Uniti 20
OM - Oman 19
PE - Perù 19
SN - Senegal 19
UZ - Uzbekistan 19
CR - Costa Rica 18
CZ - Repubblica Ceca 18
KZ - Kazakistan 18
PY - Paraguay 17
GR - Grecia 16
LT - Lituania 15
PT - Portogallo 15
JM - Giamaica 14
NP - Nepal 13
EE - Estonia 12
HU - Ungheria 12
RS - Serbia 12
AM - Armenia 11
DK - Danimarca 10
AL - Albania 8
CI - Costa d'Avorio 8
DO - Repubblica Dominicana 8
HN - Honduras 8
MD - Moldavia 8
NO - Norvegia 8
BH - Bahrain 7
ET - Etiopia 7
GE - Georgia 7
HR - Croazia 7
KG - Kirghizistan 7
UY - Uruguay 7
BO - Bolivia 6
LB - Libano 6
SK - Slovacchia (Repubblica Slovacca) 6
SV - El Salvador 6
SY - Repubblica araba siriana 6
BA - Bosnia-Erzegovina 5
GT - Guatemala 5
KW - Kuwait 5
LV - Lettonia 5
MN - Mongolia 5
MT - Malta 5
SI - Slovenia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AO - Angola 4
BY - Bielorussia 4
Totale 49.098
Salva come PNG Salva come JPEG
Città #
Warsaw 4.651
Fairfield 2.614
Ashburn 2.562
Singapore 2.428
Woodbridge 1.993
Houston 1.638
Ann Arbor 1.351
Hong Kong 1.291
San Jose 1.167
Chandler 1.115
Wilmington 1.103
Seattle 1.088
Cambridge 959
Jacksonville 605
Trieste 487
Beijing 478
Seoul 477
Princeton 472
Boardman 458
Hefei 395
Santa Clara 377
Chicago 351
Council Bluffs 348
Dallas 327
Columbus 314
Izmir 312
Ho Chi Minh City 298
Amsterdam 287
Lauterbourg 279
Dublin 273
Sofia 261
Los Angeles 238
Zgierz 226
Moscow 221
Hanoi 220
Milan 207
Helsinki 198
The Dalles 190
New York 169
Buffalo 134
San Diego 131
Frankfurt am Main 122
Dong Ket 108
São Paulo 107
London 99
Munich 98
Rome 74
Dearborn 68
Tokyo 68
Falls Church 64
Phoenix 62
Nuremberg 61
Orem 57
Casablanca 52
Lappeenranta 52
Bremen 51
Tianjin 51
Redondo Beach 50
Shanghai 50
Atlanta 48
Da Nang 48
Rio de Janeiro 48
Toronto 48
Düsseldorf 47
Guangzhou 45
Brussels 44
Miano 44
Turku 44
San Francisco 42
Vienna 42
Norwalk 39
Redwood City 39
Dongguan 37
Hangzhou 37
Chennai 34
Kerken 34
Montreal 34
Boston 33
Brasília 33
Haiphong 33
Denver 32
Johannesburg 32
Brooklyn 30
Duino-Aurisina 30
Des Moines 29
Riyadh 29
Venice 28
Barcelona 27
Shenzhen 27
Redmond 26
Tel Aviv 26
Mumbai 25
Florence 24
Nanjing 24
Mexico City 23
Stockholm 23
Baghdad 22
Belo Horizonte 22
Fremont 22
Jinan 22
Totale 35.363
Salva come PNG Salva come JPEG
Nome #
Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma 455
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration 435
Advances in systemic therapy for metastatic breast cancer: future perspectives 420
NEODUCTGENESIS AS A PROGNOSTIC MARKER IN “DUCTAL” CARCINOMA IN SITU OF THE BREAST 404
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial 403
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene 400
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer 396
Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? 395
Isolated testicular metastasis from prostate cancer 376
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study 375
Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer 370
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma 368
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma 368
Designing a broad-spectrum integrative approach for cancer prevention and treatment 366
Current challenges in HER2-positive breast cancer 361
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition 356
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 350
Broad targeting of angiogenesis for cancer prevention and therapy 349
Bevacizumab in small cell lung cancer 349
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer 347
Characterization of MTAP gene expression in breast cancer patients and cell lines 341
Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer 341
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 337
Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts 327
Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study 325
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials 324
Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer? 322
Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes 318
Abemaciclib: A CDK4/6 inhibitor for the treatment of HR+/HEeR2- advanced breast cancer 310
Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma 306
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 304
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma 284
The relevance of chemobrain in breast cancer survivors: An Italian exploratory study to measure incidence and psycho-social impact 282
Apatinib for the treatment of gastric cancer 280
Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer 279
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 277
Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers 277
Advances in systemic therapy for malignant mesothelioma: Future perspectives 276
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit 275
Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. 273
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 267
Lenvatinib for the treatment of renal cell carcinoma 264
Inhibitors of Tumor Angiogenesis 261
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 256
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 248
PROGNOSTIC ROLE OF TUMOR INFILTRATING LYMPHOCITES (TILS) IN EPITHELIOID PLEURAL MESOTHELIOMA 244
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis 243
Colorectal cancer-screening program improves both short- and long-term outcomes: a single-center experience in Trieste 242
The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis 240
CDK4/6 inhibitors in HER2-positive breast cancer 239
Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis 234
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment 231
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials 230
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study 228
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making 226
Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR 224
Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives (Medical Oncology, (2017), 34, 7, (119), 10.1007/s12032-017-0975-5) 219
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer 218
Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? 216
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting 216
Practice patterns regarding drains management in breast surgery: Results of a survey of Senonetwork Italia breast centers 210
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET) 209
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data 209
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 208
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 205
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 205
RNA disruption and drug response in breast cancer primary systemic therapy 203
Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer? 201
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? 201
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer 199
Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status 198
Ibrutinib: from bench side to clinical implications 198
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer 197
High-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk primary breast cancer 195
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: The OnCovid Inflammatory Score 195
Neoadjuvant treatment approach: The rosetta stone for breast cancer? 192
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report 190
Granular cell tumor of the breast: a multidisciplinary challenge 189
A Phase II study of olaparib in breast cancer patients: Biological evaluation from a 'window of opportunity' trial 186
Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials 185
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 184
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer 182
"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future? 182
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer 182
Breast cancer circulating biomarkers: advantages, drawbacks, and new insights 181
Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer 179
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy 179
Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials 177
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 176
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer 176
Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: A Meta-analysis 176
Evaluation of circulating cell-free DNA and its integrity as a potential predictive biomarker of breast cancer onset: A pilot study 176
Impact of psychosocial, behavioral and lifestyle factors on subjective cognitive complaints and perceived quality of life in a large cohort of Italian breast cancer patients 175
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients 174
Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer? 173
Posterior Petrous Meningiomas: Surgical Classification and Postoperative Outcomes in a Case Series of 130 Patients Operated via the Retrosigmoid Approach 172
Neoadjuvant model in cancer treatment: From clinical opportunity to health-care utility 171
Gene expression profiling in breast cancer: A clinical perspective 170
Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: A rhythmometric analysis 170
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 170
Totale 25.947
Salva come PNG Salva come JPEG
Categoria #
all - tutte 145.512
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 145.512
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021357 0 0 0 0 0 0 0 0 0 0 0 357
2021/20222.804 163 409 197 173 39 197 134 107 380 380 172 453
2022/20233.528 335 361 295 433 368 653 54 313 427 39 178 72
2023/20242.825 120 364 163 188 162 226 476 594 24 122 217 169
2024/20256.728 96 524 834 424 589 943 274 378 769 750 548 599
2025/202614.808 1.205 866 879 1.002 1.289 1.174 2.215 569 1.717 2.266 898 728
Totale 50.215